2117 SW HIGHWAY 484, OCALA, FL
Shareholder votes
Regains NYSE American Compliance
Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
AIM ImmunoTech Inc. Amends Bylaws to Change Voting Standard
Investor Presentation
AIM ImmunoTech Inc. Enters Securities Purchase Agreement for 7.5M Shares
Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities
Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Q1
FY 2025
Notice of Late Filing for Quarterly Report
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
S-1
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Definitive Additional Information Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload